Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Fibulo-ulnar hypoplasia-renal anomalies syndrome is characterized by fibuloulnar dysostosis with renal anomalies. It has been described in two sibs born to nonconsanguinous parents. The syndrome is lethal at birth (respiratory failure). Clinical manifestations include ear and facial anomalies (including micrognathia), symmetrical shortness of long bones, fibular agenesis and hypoplastic ulna, oligosyndactyly, congenital heart defects, and cystic or hypoplastic kidney. It is transmitted as an autosomal recessive trait.
Biomarker and diagnostic research for Fibulo-ulnar hypoplasia-renal anomalies syndrome has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Fibulo-ulnar hypoplasia-renal anomalies syndrome.
198 publications have been identified in PubMed for Fibulo-ulnar hypoplasia-renal anomalies syndrome. Research spans Review / Meta-Analysis (52%), Basic Science / Preclinical (26%), and Epidemiology / Natural History (7%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 86 | 52% |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 8:30 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Fibulo-ulnar hypoplasia-renal anomalies syndrome
Laboratory research
42 |
26% |
Disease patterns and progression | 12 | 7% |
Patient case studies | 11 | 7% |
Testing and diagnosis research | 7 | 4% |
Clinical study results | 4 | 2% |
Other research | 2 | 1% |
Papazachariou A (2026). [PMID: 41128447](https://pubmed.ncbi.nlm.nih.gov/41128447/). *Curr Opin Clin Nutr Metab Care*. [Review / Meta-Analysis]
Lee S (2026). [PMID: 41206258](https://pubmed.ncbi.nlm.nih.gov/41206258/). *Am J Geriatr Psychiatry*. [Review / Meta-Analysis]
Sebode M (2026). [PMID: 41432137](https://pubmed.ncbi.nlm.nih.gov/41432137/). *Current opinion in gastroenterology*. [Review / Meta-Analysis]
Anderson EN (2026). [PMID: 41468891](https://pubmed.ncbi.nlm.nih.gov/41468891/). *Am J Hum Genet*. [Basic Science / Preclinical]
Rheault MN (2026). [PMID: 40938675](https://pubmed.ncbi.nlm.nih.gov/40938675/). *J Am Soc Nephrol*. [Review / Meta-Analysis]
Amado C (2026). [PMID: 40975490](https://pubmed.ncbi.nlm.nih.gov/40975490/). *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology*. [Clinical Trial Publication]
Verbinnen I (2025). [PMID: 39978342](https://pubmed.ncbi.nlm.nih.gov/39978342/). *American journal of human genetics*. [Basic Science / Preclinical]
Jachiet V (2025). [PMID: 40476413](https://pubmed.ncbi.nlm.nih.gov/40476413/). *La Revue du praticien*. [Review / Meta-Analysis]
Fann Marko R (2025). [PMID: 39987477](https://pubmed.ncbi.nlm.nih.gov/39987477/). *Harefuah*. [Review / Meta-Analysis]
Zoref-Lorenz A (2025). [PMID: 39656557](https://pubmed.ncbi.nlm.nih.gov/39656557/). *Leukemia & lymphoma*. [Review / Meta-Analysis]